Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323661" target="_blank" >RIV/00064203:_____/16:10323661 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10323661
Result on the web
<a href="http://dx.doi.org/10.1080/2162402X.2015.1088631" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1088631</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2015.1088631" target="_blank" >10.1080/2162402X.2015.1088631</a>

Result language
angličtina
Original language name
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Original language description
Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)